Your session is about to expire
← Back to Search
Capivasertib for Cancer
Study Summary
This trial is testing the effects of AZD5363 on patients with cancer that has a genetic change called AKT mutation. AZD5363 may block AKT, which is a protein needed for cancer cell growth.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not allergic to AZD5363 or similar medications.My cancer does not have KRAS, NRAS, HRAS, or BRAF mutations.My recent ECG showed no significant heart issues.My breast cancer is hormone receptor positive, HER2 negative, and has not been removed by surgery.I have diabetes or am at risk but my fasting glucose is under 160 mg/dL, I don't use insulin, and I take two or fewer diabetes pills.I haven't taken PI3K, AKT, or mTOR inhibitors for my cancer, except for short trials or approved rapalogs.I haven't taken strong medication that affects liver enzymes in the last 2-3 weeks.My cancer has an AKT mutation.
- Group 1: Treatment (capivasertib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what extent has the recruitment of participants been successful for this research endeavor?
"Unfortunately, the study is not currently accepting new enrollees. It was initially presented on May 31st 2016 and last updated 9/16/2022. For those seeking other suitable studies, there are 4669 clinical trials for neoplasms and plasma cell diseases along with 21 Capivasertib studies that require participants at this time."
Has Capivasertib been accepted by the FDA?
"Our assessment of Capivasertib's safety is 2, as the drug has passed through Phase 2 clinical trials with evidence suggesting it is safe but no attestations to its efficacy."
Are there current opportunities for volunteers to join the trial?
"Accurate. The clinical trial registry indicates that this particular research project is not currently recruiting participants, despite being last amended on September 16th 2022. Nevertheless, there are 4690 other trials open to patient enrolment at the time of writing."
Has this experiment been conducted before, or is it a pioneering endeavor?
"Since 2010, Capivasertib has been subject to ongoing research. AstraZeneca initially sponsored a study with 285 participants that granted it Phase 1 drug approval in the same year. In its wake, 21 clinical trials are currently running worldwide from 961 cities and 44 countries."
Can you provide information regarding preceding trials involving Capivasertib?
"At present, 21 trials are underway to evaluate the efficacy of Capivasertib. Among these studies, 4 have reached phase 3 and there is a total of 4194 sites participating in the research across Montpellier and Ontario."
Share this study with friends
Copy Link
Messenger